Vlad Vitoc, Chief Executive Officer and Director of MAIA Biotechnology, Inc., filed a Form 4 on November 17, 2026, disclosing two open-market purchases of MAIA common stock totaling 100,000 shares made on November 13 and November 16, 2026.
Key Highlights
- First purchase: Vitoc acquired 60,400 shares of common stock on November 13, 2026, at a price of $1 per share.
- Second purchase: Vitoc acquired 39,600 shares on November 16, 2026, at a weighted average price, with individual transaction prices ranging from $0.9905 to $1.0000, inclusive.
- Direct ownership after transactions: Vitoc directly holds 1,149,121 shares of common stock following the two reported purchases.
- Indirect ownership: An additional 210,100 shares are reported as indirectly beneficially owned through Vitoc's spouse, with the filing noting he disclaims beneficial ownership except to the extent of his pecuniary interest.
- Transaction codes: Both transactions are coded "P" (open-market purchase) in the filing.
- Roles: Vitoc is identified in the filing as Director, 10% Owner, and Chief Executive Officer of MAIA Biotechnology, Inc.
Vitoc's November Purchases and Beneficial Ownership in MAIA Biotechnology
According to the Form 4 filed with the SEC on November 17, 2026, Vlad Vitoc reported two separate purchases of MAIA Biotechnology, Inc. common stock traded under the ticker MAIA. The first transaction, dated November 13, 2026, involved the acquisition of 60,400 shares at $1 per share, bringing his direct holdings at that point to 1,109,521 shares, as reported in the filing.
The second transaction occurred on November 16, 2026, and involved the acquisition of 39,600 additional shares. The filing states that the price reported is a weighted average price and that the shares were purchased in multiple transactions at prices ranging from $0.9905 to $1.0000, inclusive. The filing further notes that Vitoc undertakes to provide full information regarding the number of shares purchased at each separate price within that range upon request by SEC staff, any security holder, or the issuer. Following this purchase, the filing reports Vitoc's direct beneficial ownership at 1,149,121 shares.
In addition to the directly held shares, the filing discloses 210,100 shares held indirectly. According to the filing, these securities are beneficially owned by Vitoc's spouse, and the reporting person disclaims beneficial ownership of those shares except to the extent of his pecuniary interest in them. No derivative securities transactions were reported in this filing.
What Was Disclosed
The filing disclosed two open-market purchases by MAIA Biotechnology CEO and Director Vlad Vitoc on November 13 and 16, 2026, totaling 100,000 shares, resulting in direct beneficial ownership of 1,149,121 shares and indirect ownership of 210,100 shares via his spouse.



Please wait processing your request...